Lower baseline eosinophil counts are associated with inferior survival in Mantle cell lymphoma.

Authors

Kacper Kopeć, Mateusz Fałek, Julia Piotrowska, Adrian Ławski, Julia Rojek, Kacper Pawlak, Maria Woźniak, Marta Czajkowska, Olga Raczyńska, Tadeusz Robak, Jan Wojdal, Paweł Robak, Joanna Góra-Tybor, Damian Mikulski

Published in

Leukemia & lymphoma. Pages 1-9. Oct 29, 2026. Epub Oct 29, 2026.

Abstract

Mantle cell lymphoma (MCL) is characterized by heterogeneous clinical outcomes, highlighting the need for additional biomarkers to refine risk stratification beyond established prognostic models. We evaluated the prognostic value of baseline absolute eosinophil count (EOZ) in 144 adults with newly diagnosed MCL treated with first-line immunochemotherapy. The median EOZ was 0.10 × 10⁹/L. Patients with EOZ above the median had longer OS (84.8 vs. 31.6 months; log-rank p = 0.004) and PFS (64.6 vs. 18.5 months; p = 0.002). In multivariable analyses, each doubling of EOZ was associated with lower hazards of death (HR 0.73, 95% CI 0.61-0.87; p < 0.001) and progression or death (HR 0.76, 95% CI 0.65-0.89; p < 0.001). At 3 years, the incident/dynamic AUC increased from 0.674 to 0.707 for OS (p = 0.042) and from 0.653 to 0.680 for PFS (p = 0.057). Higher baseline EOZ was independently associated with favorable outcome in MCL, supporting further evaluation and validation in independent cohorts.

PMID:
42958845
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.